Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
151-165 of 2367 results
Takeda secures rights to Mersana’s XMT-1522 outside US and Canada
Mersana Therapeutics and Takeda Pharmaceutical Company have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the US and Canada.
Contract Research & Services > Contract Services > News
Eisai, Esteve sign deal to co-promote anti-epilepsy drug Fycompa in Spain
Eisai has entered into a new agreement with Esteve to co-promote Fycompa (perampanel) in Spain from February 2016.
Contract Research & Services > Contract Services > News
Ligand inks OmniAb platform license deal with Tizona Therapeutics
Ligand Pharmaceuticals has entered into a worldwide license agreement with Tizona Therapeutics, an immunology company developing next generation therapies for cancer and autoimmune disease.
Contract Research & Services > Contract Services > News
Teva and AbCellera sign deal to discover rare monoclonal antibodies
Teva Pharmaceutical Industries and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies.
Contract Research & Services > Contract Services > News
Eisai acquires license from HUYA to develop HDAC inhibitor HBI-8000
Eisai has entered into an exclusive license agreement with HUYA Bioscience International to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.
Contract Research & Services > Contract Services > News
Bristol-Myers Squibb, Pfizer collaborate with Portola to develop andexanet alfa in Japan
Bristol-Myers Squibb and Pfizer have entered into a collaboration agreement with Portola Pharmaceuticals to develop and commercialize the investigational agent andexanet alfa in Japan.
Contract Research & Services > Contract Services > News
Avera Medical, Epic Sciences partner on cancer precision medicine clinical trials
Epic Sciences and Avera Medical Group have formed a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast cancer clinical trials.
Contract Research & Services > Contract Services > News
Radius Health partners with Novartis to evaluate RAD1901 combination regimens in advanced breast cancer
Radius Health has entered into a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader (SERD), with investigational agent LEE011 (ribociclib), a cyclin-dependent kinase (CDK) 4/6 inhibitor.
Contract Research & Services > Contract Services > News
Myeloma UK partners with SGC to accelerate discovery of myeloma treatment targets
Myeloma UK has entered into a new first-of-its-kind partnership to help bring treatments to myeloma patients faster.
Contract Research & Services > Contract Services > News
Pharnext partners with OrphanDev for phase 3 trial of PXT-3003 to treat CMT 1A
Pharnext has formed a collaboration with OrphanDev, a dedicated platform offering support in regulatory, methodology and logistics for rare diseases.
Contract Research & Services > Contract Services > News
Medigene partners with Swiss university to characterize T cell receptors
By PBR Staff Writer
Medigene has signed a collaboration agreement with the University of Lausanne, Switzerland, to explore new technologies for the characterization of its T cell receptors (TCRs).
Contract Research & Services > Contract Services > News
Broad Institute Genomic Services partners with Takeda to perform genomic analysis on patient samples from phase 3 clinical trial of NINLARO
Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO (ixazomib), an oral proteasome inhibitor that was recently approved by the US Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Contract Research & Services > Contract Services > News
Stellar, Neovacs propose to form JV to manufacture conjugated therapeutic vaccines
Stellar Biotechnologies and Neovacs have entered into a term sheet to form a joint venture for the manufacture of conjugated therapeutic vaccines (the Joint Venture) using Stellar's Keyhole Limpet Hemocyanin (KLH).
Contract Research & Services > Contract Services > News
Immunovia, UK university partner to validate early detection blood test for pancreatic cancer
In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced that the first European site participating in its prospective clinical study for the early diagnosis of pancreatic cancer will be the National Institute for Health Research (NIHR) Pancreatic Biomedical Research Unit, based at the Royal Liverpool University Hospital.
Contract Research & Services > Contract Services > News
Santhera signs distribution deal with Ewopharma for Raxone
By PBR Staff Writer
Santhera Pharmaceuticals has signed a distribution and supply agreement with Ewopharma for Raxone covering Eastern European countries and the Baltics.
Contract Research & Services > Contract Services > News
151-165 of 2367 results